EGFR and colorectal cancer: For colorectal cancer, CodeBreak 300 is an actively recruiting Phase 3 clinical trial for refractory metastatic cancer, evaluating Sotorasib in combination with Panitumumab (EGFR inhibitor) versus either TAS-102 or Regorafenib [68].